Superparamagnetic Iron Oxide Nanoparticles Reprogram the Tumor Microenvironment and Reduce Lung Cancer Regrowth after...

Area of Science:

• Oncology
• Nanomedicine
• Immunotherapy

Background:

• ALK-positive non-small cell lung cancer (NSCLC) patients initially respond to ALK tyrosine kinase inhibitors (TKIs) but develop resistance, leading to poor survival.
• Tumor-associated macrophages (TAMs) promote lung cancer growth and immunosuppression, hindering effective immunotherapy in ALK-positive NSCLC.
• Reprogramming TAMs towards a pro-inflammatory, tumor-suppressive phenotype is a promising therapeutic strategy.

Purpose of the Study:

• To investigate the efficacy of superparamagnetic iron oxide nanoparticles containing core-cross-linked polymer micelles (SPION-CCPMs) in reprogramming TAMs.
• To evaluate SPION-CCPMs' ability to enhance anti-tumor immunity and overcome TKI resistance in ALK-positive lung cancer.
• To assess SPION-CCPMs as an adjuvant therapy to improve patient survival in ALK-positive NSCLC.

Main Methods:

• SPION-CCPMs were synthesized and characterized for their ability to target macrophages.
• The study assessed SPION-CCPMs' effect on TAM phenotype, cytokine secretion, and reactive nitrogen species production.
• In vivo studies involved intratracheal instillation of SPION-CCPMs in a mouse model of ALK-positive lung cancer, combined with TKI therapy.

Main Results:

• SPION-CCPMs stimulated TAMs to secrete tumoricidal reactive nitrogen species and cytokines.
• SPION-CCPMs remodeled the immunosuppressive tumor microenvironment (TME) by recruiting CD8+ T cells.
• Intratracheal SPION-CCPM administration delayed tumor growth and halted tumor regrowth after TKI treatment in mice.

Conclusions:

• SPION-CCPMs effectively reprogram TAMs, exhibiting direct tumoricidal activity and reshaping the TME towards a cytotoxic profile.
• SPION-CCPMs demonstrate significant potential as an adjuvant therapy to overcome TKI resistance and delay the emergence of resistant tumors in ALK-positive NSCLC.
• This nanomedicine approach offers a novel strategy to enhance immunotherapy response in previously non-responsive ALK-positive lung cancer patients.